Aclaris shareholders back board, pay and PwC
Aclaris Therapeutics, Inc. held its 2026 annual meeting of stockholders on June 4, 2026.
Rhea-AI Filing Summary
Aclaris Therapeutics, Inc. held its 2026 annual meeting of stockholders on June 4, 2026. Stockholders representing 112,499,671 shares, or approximately 80.55% of the 139,663,680 shares outstanding as of the record date, were present or represented by proxy, providing a strong quorum.
Two directors, Anand Mehra, M.D. and Maxine Gowen, Ph.D., were elected to serve until the 2029 annual meeting. An advisory vote approved the compensation of the company’s named executive officers. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding at record date: 139,663,680 shares
Shares represented at meeting: 112,499,671 shares
Quorum percentage: 80.55%
+4 more
7 metrics
Shares outstanding at record date
139,663,680 shares
Outstanding as of the record date for the 2026 annual meeting
Shares represented at meeting
112,499,671 shares
Approximately 80.55% of shares outstanding present or by proxy
Quorum percentage
80.55%
Portion of 139,663,680 outstanding shares represented at the meeting
Say-on-pay votes for
83,370,124 votes
Advisory approval of named executive officer compensation
Say-on-pay votes against
9,734,691 votes
Advisory vote on executive compensation
Auditor ratification votes for
112,322,811 votes
Ratification of PricewaterhouseCoopers LLP for fiscal year 2026
Auditor ratification votes against
159,714 votes
Vote on selection of independent registered public accounting firm
Key Terms
broker non-votes, independent registered public accounting firm, advisory basis, named executive officers
4 terms
broker non-votes financial
"Broker Non-Votes 83,370,124 | 9,734,691 | 34,378 | 19,360,478"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
advisory basis financial
"The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers"
named executive officers financial
"the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement"
Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was the quorum at Aclaris Therapeutics (ACRS) 2026 annual meeting?
Stockholders representing approximately 80.55% of outstanding shares were present or represented by proxy. That was 112,499,671 shares out of 139,663,680 outstanding as of the record date, indicating strong participation in the meeting.
Which directors were elected at Aclaris Therapeutics (ACRS) 2026 annual meeting?
Stockholders elected Anand Mehra, M.D. and Maxine Gowen, Ph.D. as directors. They will serve on the Board of Directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified.
What were the vote totals for Aclaris director Anand Mehra at the 2026 meeting?
For director nominee Anand Mehra, M.D., stockholders cast 83,063,569 votes for and 10,075,624 votes withheld. There were also 19,360,478 broker non-votes recorded on this director election proposal.
What were the vote totals for Aclaris director Maxine Gowen at the 2026 meeting?
For director nominee Maxine Gowen, Ph.D., stockholders cast 84,209,108 votes for and 8,930,085 votes withheld. As with the other director election, there were 19,360,478 broker non-votes on this proposal.
AI-generated analysis. How Rhea-AI works. Not financial advice.
